The randomised, controlled and double-blind study will recruit 352 patients in between 25 and 30 medical centres and hospitals in North America. The multicentre study will evaluate the
TNF-α is a proinflammatory cytokine that has been implicated in the pathogenesis of sarcoidosis and associated granuloma formation. “We are pleased the FDA has granted Orphan Drug Designation
Based in New York, Prevail develops and commercialises disease-modifying Adeno-associated viruses (AAV) based gene therapies to treat neurodegenerative diseases. Under the deal, Eli Lilly will acquire Prevail by paying
PAH is a rare and chronic progressing disorder characterised by the narrowing of small pulmonary arteries and inflated blood pressure in the pulmonary circulation. Sotatercept, an investigational reverse-remodelling
InvisiMask is an intra-nasal application of a proprietary human monoclonal antibody that is intended to be used as a prophylactic against contracting SARS-CoV-2 infection. Results of the study,
Via newly established Swedish limited liability company Roar BidCo AB, EQT IX has announced a public offer of SEK220 ($26.1) in cash per share to the shareholders of
Leqvio, a first-in-class small interfering RNA (siRNA), has been approved based on data from the ORION clinical development programme. The approval allows to use Leqvio in combination with
The vaccine is now authorized under an Emergency Use Authorization (EUA) while Pfizer and BioNTech gather additional data and prepare to file a planned Biologics License Application (BLA)
Under the deal, Alexion shareholders will secure $60 in cash and 2.1243 new AstraZeneca American depositary shares (ADSs) listed on the Nasdaq exchange for each of their Alexion
Sotorasib, which is claimed to be the first KRAS G12C inhibitor to enter the clinic, is being assessed in the wide clinical programme examining 10 combinations with global
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.